Therapeutic Area | MeSH |
---|---|
hemic and lymphatic diseases | D006425 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
VONJO | CTI Biopharma | N-208712 RX | 2022-02-28 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
vonjo | New Drug Application | 2024-11-19 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
primary myelofibrosis | — | D055728 | D47.4 |
Expiration | Code | ||
---|---|---|---|
PACRITINIB CITRATE, VONJO, CTI BIOPHARMA CORP | |||
2029-02-28 | ODE-397 | ||
2027-02-28 | NCE |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Primary myelofibrosis | D055728 | — | D47.4 | 3 | 3 | 2 | — | — | 8 |
Polycythemia vera | D011087 | — | D45 | — | 2 | 2 | — | — | 4 |
Essential thrombocythemia | D013920 | — | D47.3 | — | 1 | 2 | — | — | 3 |
Thrombocytosis | D013922 | — | D75.83 | — | 1 | 2 | — | — | 3 |
Polycythemia | D011086 | EFO_0005804 | D75.1 | — | 1 | 2 | — | — | 3 |
Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Leukemia | D007938 | — | C95 | 2 | 1 | — | — | — | 3 |
Myelodysplastic syndromes | D009190 | — | D46 | 1 | 1 | — | — | — | 2 |
Preleukemia | D011289 | — | — | 1 | 1 | — | — | — | 2 |
Neoplasms | D009369 | — | C80 | 1 | 1 | — | — | — | 2 |
Myeloproliferative disorders | D009196 | — | D47.1 | 1 | 1 | — | — | — | 2 |
Graft vs host disease | D006086 | — | D89.81 | 1 | 1 | — | — | — | 1 |
Covid-19 | D000086382 | — | U07.1 | — | 1 | — | — | — | 1 |
Colorectal neoplasms | D015179 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 5 | — | — | — | — | 5 |
Drug interactions | D004347 | — | — | 2 | — | — | — | — | 2 |
Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
Myeloid leukemia | D007951 | — | C92 | 1 | — | — | — | — | 1 |
Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | — | — | — | — | 1 |
Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 1 | — | — | — | — | 1 |
Myelomonocytic leukemia acute | D015479 | — | C92.5 | 1 | — | — | — | — | 1 |
Leukemia myeloid chronic atypical bcr-abl negative | D054438 | — | C92.2 | 1 | — | — | — | — | 1 |
Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | 1 | — | — | — | — | 1 |
Syndrome | D013577 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Pacritinib |
INN | pacritinib |
Description | Pacritinib, sold under the brand name Vonjo, is an anti-cancer medication used to treat myelofibrosis. It is a macrocyclic protein kinase inhibitor. It mainly inhibits Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3\CD135 (FLT3).
|
Classification | Small molecule |
Drug class | tyrosine kinase inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | C1=N/C2=N/c3ccc(OCCN4CCCC4)c(c3)COC/C=C/COCc3cccc(c3)C(=C1)N2 |
PDB | — |
CAS-ID | 937272-79-2 |
RxCUI | — |
ChEMBL ID | CHEMBL2035187 |
ChEBI ID | — |
PubChem CID | 46216796 |
DrugBank | DB11697 |
UNII ID | G22N65IL3O (ChemIDplus, GSRS) |